Burney Co. Purchases Shares of 38,699 Qiagen N.V. $QGEN

Burney Co. acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 38,699 shares of the company’s stock, valued at approximately $1,729,000.

Other large investors also recently modified their holdings of the company. MAI Capital Management boosted its holdings in shares of Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares during the period. Farther Finance Advisors LLC lifted its position in Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after acquiring an additional 849 shares during the last quarter. Allworth Financial LP lifted its position in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after acquiring an additional 796 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Qiagen by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after acquiring an additional 980 shares during the period. Finally, Cullen Frost Bankers Inc. grew its position in shares of Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after purchasing an additional 1,183 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Performance

NYSE:QGEN opened at $45.30 on Monday. The stock has a fifty day moving average price of $46.10 and a 200-day moving average price of $47.11. The company has a market cap of $10.07 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88.

Qiagen’s stock is scheduled to reverse split on the morning of Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.57 EPS. As a group, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $55.00 to $50.00 in a research report on Thursday, December 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 22nd. Finally, Barclays restated an “overweight” rating and issued a $55.00 price target (up from $53.00) on shares of Qiagen in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $49.61.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.